PortalPublikationenImpact of transcatheter aortic valve implantation (TAVI) on ...

Impact of transcatheter aortic valve implantation (TAVI) on pulmonary hyper-tension and clinical outcome in patients with severe aortic valvular stenosis

Standard

Impact of transcatheter aortic valve implantation (TAVI) on pulmonary hyper-tension and clinical outcome in patients with severe aortic valvular stenosis. / Schewel, Dimitry; Schewel, Jury; Martin, Julia; Voigtländer, Lisa; Frerker, Christian; Wohlmuth, Peter; Thielsen, Thomas; Kuck, Karl-Heinz; Schäfer, Ulrich.

in: CLIN RES CARDIOL, Jahrgang 104, Nr. 2, 02.2015, S. 164-174.

Publikationen: SCORING: Beitrag in Fachzeitschrift/Zeitung › SCORING: Zeitschriftenaufsatz › Forschung › Begutachtung

Harvard

Schewel, D, Schewel, J, Martin, J, Voigtländer, L, Frerker, C, Wohlmuth, P, Thielsen, T, Kuck, K-H & Schäfer, U 2015, 'Impact of transcatheter aortic valve implantation (TAVI) on pulmonary hyper-tension and clinical outcome in patients with severe aortic valvular stenosis', CLIN RES CARDIOL, Jg. 104, Nr. 2, S. 164-174. https://doi.org/10.1007/s00392-014-0772-5

APA

Schewel, D., Schewel, J., Martin, J., Voigtländer, L., Frerker, C., Wohlmuth, P., Thielsen, T., Kuck, K-H., & Schäfer, U. (2015). Impact of transcatheter aortic valve implantation (TAVI) on pulmonary hyper-tension and clinical outcome in patients with severe aortic valvular stenosis. CLIN RES CARDIOL, 104(2), 164-174. https://doi.org/10.1007/s00392-014-0772-5

Vancouver

Schewel D, Schewel J, Martin J, Voigtländer L, Frerker C, Wohlmuth P et al. Impact of transcatheter aortic valve implantation (TAVI) on pulmonary hyper-tension and clinical outcome in patients with severe aortic valvular stenosis. CLIN RES CARDIOL. 2015 Feb;104(2):164-174. https://doi.org/10.1007/s00392-014-0772-5

Bibtex

@article{275e256045d14abb846c27048ed0a956,
title = "Impact of transcatheter aortic valve implantation (TAVI) on pulmonary hyper-tension and clinical outcome in patients with severe aortic valvular stenosis",
abstract = "BACKGROUND: Transcatheter aortic valve implantation (TAVI) is a proven alternative to open heart surgery in elderly patients. Pulmonary hypertension (PH) is known as a significant risk factor in patients with severe aortic stenosis (AS) undergoing surgical aortic valve replacement. However, the prognostic impact of PH in high-risk patients undergoing TAVI is still unknown. The aim of this study was to gain more insight in the clinical outcome and mortality of patients with PH after TAVI.METHODS AND RESULTS: Between July 2009 and September 2012, a total of 439 patients were treated by TAVI in conjunction with a complete invasive right heart study at our institution. Patients were divided into two groups with regard to their pulmonary arterial mean pressure (PAMP) before TAVI (A: PAMP < 25 mmHg and B: PAMP ≥ 25 mmHg). Patients with baseline PH had a significantly higher logES (A: 19.40 vs. B: 28.17 %; p < 0.001) and were more frequently in NYHA functional class IV (A: 15.4 vs. B: 25.1 %; p = 0.013). Invasive right heart data demonstrated an immediate improvement after TAVI in patients with PH. Despite a similar clinical benefit among survivors, 30-day and 1-year mortality were higher in patients with PH (30-day mortality: A: 4.8 vs. B: 10.4 %; p = 0.021, 1 year mortality: A: 13.9 vs. B: 23.4 %; p = 0.014).CONCLUSIONS: Pulmonary hypertension is an independent risk factor for survival after TAVI. Nevertheless, TAVI leads to an acute improvement of nearly all invasively assessed variables in patients with PH, with a similar improvement in functional NYHA class compared to patients without PH, indicating a similar benefit among survivors.",
keywords = "Age Distribution, Aged, Aged, 80 and over, Aortic Valve Stenosis/mortality, Comorbidity, Female, Germany/epidemiology, Humans, Hypertension, Pulmonary/mortality, Incidence, Male, Middle Aged, Prognosis, Risk Factors, Sex Distribution, Survival Rate, Transcatheter Aortic Valve Replacement/mortality, Treatment Outcome",
author = "Dimitry Schewel and Jury Schewel and Julia Martin and Lisa Voigtl{\"a}nder and Christian Frerker and Peter Wohlmuth and Thomas Thielsen and Karl-Heinz Kuck and Ulrich Sch{\"a}fer",
year = "2015",
month = feb,
doi = "10.1007/s00392-014-0772-5",
language = "English",
volume = "104",
pages = "164--174",
journal = "CLIN RES CARDIOL",
issn = "1861-0684",
publisher = "D. Steinkopff-Verlag",
number = "2",

}

RIS

TY - JOUR

T1 - Impact of transcatheter aortic valve implantation (TAVI) on pulmonary hyper-tension and clinical outcome in patients with severe aortic valvular stenosis

AU - Schewel, Dimitry

AU - Schewel, Jury

AU - Martin, Julia

AU - Voigtländer, Lisa

AU - Frerker, Christian

AU - Wohlmuth, Peter

AU - Thielsen, Thomas

AU - Kuck, Karl-Heinz

AU - Schäfer, Ulrich

PY - 2015/2

Y1 - 2015/2

N2 - BACKGROUND: Transcatheter aortic valve implantation (TAVI) is a proven alternative to open heart surgery in elderly patients. Pulmonary hypertension (PH) is known as a significant risk factor in patients with severe aortic stenosis (AS) undergoing surgical aortic valve replacement. However, the prognostic impact of PH in high-risk patients undergoing TAVI is still unknown. The aim of this study was to gain more insight in the clinical outcome and mortality of patients with PH after TAVI.METHODS AND RESULTS: Between July 2009 and September 2012, a total of 439 patients were treated by TAVI in conjunction with a complete invasive right heart study at our institution. Patients were divided into two groups with regard to their pulmonary arterial mean pressure (PAMP) before TAVI (A: PAMP < 25 mmHg and B: PAMP ≥ 25 mmHg). Patients with baseline PH had a significantly higher logES (A: 19.40 vs. B: 28.17 %; p < 0.001) and were more frequently in NYHA functional class IV (A: 15.4 vs. B: 25.1 %; p = 0.013). Invasive right heart data demonstrated an immediate improvement after TAVI in patients with PH. Despite a similar clinical benefit among survivors, 30-day and 1-year mortality were higher in patients with PH (30-day mortality: A: 4.8 vs. B: 10.4 %; p = 0.021, 1 year mortality: A: 13.9 vs. B: 23.4 %; p = 0.014).CONCLUSIONS: Pulmonary hypertension is an independent risk factor for survival after TAVI. Nevertheless, TAVI leads to an acute improvement of nearly all invasively assessed variables in patients with PH, with a similar improvement in functional NYHA class compared to patients without PH, indicating a similar benefit among survivors.

AB - BACKGROUND: Transcatheter aortic valve implantation (TAVI) is a proven alternative to open heart surgery in elderly patients. Pulmonary hypertension (PH) is known as a significant risk factor in patients with severe aortic stenosis (AS) undergoing surgical aortic valve replacement. However, the prognostic impact of PH in high-risk patients undergoing TAVI is still unknown. The aim of this study was to gain more insight in the clinical outcome and mortality of patients with PH after TAVI.METHODS AND RESULTS: Between July 2009 and September 2012, a total of 439 patients were treated by TAVI in conjunction with a complete invasive right heart study at our institution. Patients were divided into two groups with regard to their pulmonary arterial mean pressure (PAMP) before TAVI (A: PAMP < 25 mmHg and B: PAMP ≥ 25 mmHg). Patients with baseline PH had a significantly higher logES (A: 19.40 vs. B: 28.17 %; p < 0.001) and were more frequently in NYHA functional class IV (A: 15.4 vs. B: 25.1 %; p = 0.013). Invasive right heart data demonstrated an immediate improvement after TAVI in patients with PH. Despite a similar clinical benefit among survivors, 30-day and 1-year mortality were higher in patients with PH (30-day mortality: A: 4.8 vs. B: 10.4 %; p = 0.021, 1 year mortality: A: 13.9 vs. B: 23.4 %; p = 0.014).CONCLUSIONS: Pulmonary hypertension is an independent risk factor for survival after TAVI. Nevertheless, TAVI leads to an acute improvement of nearly all invasively assessed variables in patients with PH, with a similar improvement in functional NYHA class compared to patients without PH, indicating a similar benefit among survivors.

KW - Age Distribution

KW - Aged

KW - Aged, 80 and over

KW - Aortic Valve Stenosis/mortality

KW - Comorbidity

KW - Female

KW - Germany/epidemiology

KW - Humans

KW - Hypertension, Pulmonary/mortality

KW - Incidence

KW - Male

KW - Middle Aged

KW - Prognosis

KW - Risk Factors

KW - Sex Distribution

KW - Survival Rate

KW - Transcatheter Aortic Valve Replacement/mortality

KW - Treatment Outcome

U2 - 10.1007/s00392-014-0772-5

DO - 10.1007/s00392-014-0772-5

M3 - SCORING: Journal article

C2 - 25367243

VL - 104

SP - 164

EP - 174

JO - CLIN RES CARDIOL

JF - CLIN RES CARDIOL

SN - 1861-0684

IS - 2

ER -